sur Biophytis (EPA:ALBPS)
Biophytis Temporarily Suspends Trading of Shares Before Refinancing
On January 6, 2025, Biophytis SA, a biotechnology firm specializing in treatments for age-related diseases, announced a temporary suspension of its shares and share warrants trading. This suspension affects its ordinary shares on the Euronext Growth market and American Depositary Shares on the OTC market. The company, based in Paris and with offices in Cambridge, USA, intends to lift the suspension upon detailing a planned refinancing transaction shortly.
Biophytis is advancing several drug candidates, notably BIO101 for muscular and other diseases. This move is seen as preparatory to financing efforts to further these clinical projects. Details of the refinancing will be unveiled when trading resumes in the coming days.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis